Moreover, loss of MCL1 delayed the onset of BCR-ABL-transformed leukemia in a mouse xenograft model, with a strong selection against clones with the MCL-1 deletion [21], suggesting MCL-1 may be a better target for inhibition in Ph+ ALL. The gene discussed is MCL1; the disease is acute lymphoblastic leukemia.